10.74
+3.47%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hbm Holdings
Its shares trade on HKEX under the ticker 2142.HK. It has been listed since 10 December 2020. In the fiscal year to 31 December 2025, it reported revenue of $158.2m and net income of $91.5m. At that date it held total assets of $500.3m and shareholders' equity of $367.1m.
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The company employs 167 full-time employees The company went IPO on 2020-12-10. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Dec 2020
- Employees
- 167
- Website
- harbourbiomed.com ↗
Leadership
Pay as last reported
- Dr. Wang JingsongExecutive Chairman, Chief Executive Officer, since 2016
- Dr. Yingying ChenChief Financial Officer
- Mr. Lile LiuSenior Vice President, Head of Technology Platform
- Dr. Xiaolu TaoSenior Vice President, Head of Translational Development
- Dr. Hong Amy QueChief Technology Officer
- Mr. Xiaoxiang ChenExecutive Director, Chief Development Officer
- Mr. Weihao XuChief Strategy Officer
- Ms. Yifan GaoJoint Company Secretary
- Mr. Wing Yat LuiJoint Company Secretary
- Dr. Albert CollinsonNon-Executive Independent Director
- Mr. Irwin KamenNon-Executive Independent Director
- Ms. Chen WeiweiNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HBM Holdings Ltd. has 167 employees focused on clinical-stage biopharmaceutical research in immuno-oncology and immunology.
- Batoclimab targets multiple immune-related diseases including ITP, GO, MG, and NMOSD with a strong therapeutic focus.
- Tanfanercept addresses dry eye disease (DED) with a dedicated research and development pipeline in ophthalmology.
Weaknesses
- The company's IPO on 10 December 2020 indicates a relatively recent market entry with limited historical performance data.
- HBM Holdings Ltd. operates with a small employee base of 167, potentially limiting its R&D capacity and scalability.
- The clinical-stage focus means products are not yet commercially available, creating dependency on future regulatory approvals.
Opportunities
- Expanding the immuno-oncology portfolio to target immune-desert, immune-excluded, and inflamed tumors could attract new markets.
- The growing demand for treatments in immune thrombocytopenia (ITP) and Graves' ophthalmopathy (GO) presents market opportunities.
- Research into neuromyelitis optica spectrum disorder (NMOSD) could leverage increasing awareness and treatment needs.
Threats
- Regulatory delays in approving batoclimab for ITP, GO, MG, and NMOSD could impact revenue timelines.
- Competition in the biotechnology sector may intensify as more companies enter the immuno-oncology space.
- The clinical-stage nature of products exposes HBM to risks of trial failures or safety concerns during development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.